Biotech Growth tops bio-trust league with 47% NAV rise – Orbimed-managed Biotech Growth Trust (BIOG) recorded the rise 47% rise in NAV in 2019, representing the best performance of the 14 specialist biotech/pharma closed end investment vehicles monitored by Marten & Co. Biotech Growth’s rise in NAV was more than double that of the benchmark […]
Biotech Growth extends run of poor performance – On Friday, Biotech Growth Trust published results for the year ended 31 March 2019. Its net asset value per share rose by 5.3% and the share price by 4.6%, reflecting a slight widening in the discount. The benchmark (Nasdaq Biotechnology Index) returned 13.0%. Biotech Growth Trust has now […]
Biogen Alzheimer’s failure drags down Biotech Growth – Biogen, a key holding in Biotech Growth Trust and a component of most other biotech and healthcare portfolios, has lost a third of its value after trials of an Alzheimer’s drug failed to show any benefit. Biogen and its partner, Japanese drugmaker Eisai, said they would stop […]
Biotech Growth blames large caps for 2017/18 under-performance OrbiMed-managed Biotech Growth Trust (BIOG) blamed an overweight position in large cap stocks for under-performance against the benchmark Nasdaq Biotechnology index (NBI) in the six months to March 2018 and financial year as a whole, having recorded a 6.7% fall in NAV against a 2.2% fall for […]
Biotech Growth doubles down on Biogen and Alexion OrbiMed-managed Biotech Growth Trust (BIOG) appears to have increased its already substantial positions in Biogen and Alexion and reduced (or possibly even sold) its previously large stake in Regeneron in the last month, according to its an analysis of its top holdings by Marten & Co. The […]
Biotech Growth sells Amgen, buys Regeneron and Alexion in March OrbiMed-managed Biotech Growth Trust (BIOG) sold a large proportion of its stake in Amgen last month, while increasing its holdings in Regeneron and Alexion, according to an analysis of its top holdings disclosed in its latest factsheet. The shareholding in Amgen, which accounted for just over 10% of […]
Biotech Growth’s big-bio focus a cause of underperformance in February OrbiMed-managed Biotech Growth Trust (BIOG) saw a 3.9% fall in its NAV in February, under-performing against a 2.6% decline in the sterling-denominated value of the benchmark NASDAQ Biotechnology Index. The value of investments held by the trust were hit in the market wide sell-off in […]
Biotech Growth notches up small rise in Jan, but outlook for Feb is weaker Orbimed-managed Biotech Growth Trust (BIOG) notched up a broadly in-line performance in the otherwise strong month of January, despite seeing a major setback for one of its top 10 holdings. However, its outlook for February is looking weaker, an analysis by Marten […]
Contrasting movements likely for Biotech Growth Trust investees Orbimed-managed Biotech Growth Trust (BIOG) looks set to see some contrasting fortunes for key investments in its January update, due in the middle of next month, but could nevertheless be able to offer investors a positive report. On the plus side, the trust will have seen its investment […]
Biotech Growth Trust swaps out Celgene and Alexion for Amgen OrbiMed, the manager of the UK’s Biotech Growth Trust BIOG, has boosted the trust’s investment in Amgen at the expense of previous long-term holdings in Celgene and Alexion over the last month, according to the November portfolio update. Amgen is now the trust’s joint second largest investment (at 10% […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated
